The clinical study of using DLI+IL-2 after Mixed-HSCT in acute myelogenous leukemia / 中国医师进修杂志
Chinese Journal of Postgraduates of Medicine
;
(36)2006.
Article
in Chinese
| WPRIM
| ID: wpr-526681
ABSTRACT
Objective To approach curative effect of using DLI +IL-2 as immunobiotherapy after Mixed-HSCT in acute myelogenous leukemia.MethodAfter times of chemotherapy,8 cases of patients with acute myelogenous leukemia received Mixed-HSCT,then were treated with DLI +IL-2 for 2-7 times.Observed clinical effect for 1 to 5 years.Result DFS in 8 cases of patients with acute myelogenous leukemia received Mixed-HSCT and treated with DLI +IL-2 for 2-7 times were 62.5%.There were no GVHD.Conclusion Immuno-biotherapy with DLI +IL-2 after Mixed-HSCT in patients of acute myelogenous leukemia may be a method to increase DFS efficiently.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Postgraduates of Medicine
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS